Orbit Genomics, a pioneer in redefining precision medicine, today announced the appointment of Angie Purvis as Laboratory Director. With over 15 years of leadership in high-complexity molecular, immunological, and clinical chemistry laboratories, Purvis brings deep expertise in laboratory-developed tests (LDTs), regulatory compliance, and diagnostic innovation to the Orbit team.
“Angie’s track record in building high-quality, regulatory-compliant diagnostics makes her an invaluable addition to our leadership team,” said Dede Willis, CEO of Orbit Genomics. “Her ability to lead scientific development while navigating global regulatory pathways will help accelerate our mission to deliver personalized, preventive solutions to patients worldwide.”
Purvis is a board-certified Laboratory Director with extensive experience developing and scaling LDTs across infectious disease, oncology, and emerging health conditions. She has helped companies of all sizes implement quality management systems aligned with ISO13485 and 21 CFR 820, and brings global insight from working across the U.S., EU, and developing markets.
Angie received her BS in Biology from Centre College, earned a PhD in Biochemistry from Washington University, Department of Medicine, Division of Hematology and Oncology, and completed a postdoctoral fellowship in proteomics at the Howard Hughes Medical Institute.
“I’m excited to join Orbit Genomics at a time of rapid progress in the field,” said Purvis. “OrbiSeq’s ability to decode dynamic genomic sequences offers a transformational approach to early detection and precision care. I’m eager to contribute to a platform with such far-reaching clinical potential.”